www.medicinapropraxi.cz / Med. Praxi. 2025;22(4):236-241 / MEDICÍNA PRO PRAXI 241 PŘEHLEDOVÉ ČLÁNKY Vliv noční tepové frekvence na mortalitu pacientů s arteriální hypertenzí 9. Gillman MW, Kannel WB, Belanger A, et al. Influence of heart rate on mortality among persons with hypertension: The Framingham Study. Am Heart J. 1993;125:1148-1154. 10. Pittaras A, Kokkinos P, Faselis Ch, et al. Resting heart rate and mortality risk in hypertensive patients with no atrial fibrilation. Journal of Hypertension. 2024;42:e-Supplement 1, e50. 11. Wen ChP, Chen ChH, Nauman J, et al. Resting heart rate – The forgotten risk factor? Comparison of resting heart rate and hypertension as predictors of all-cause mortality in 692,217 adults in Asia and Europe. Progress in cardiovascular diseases. 2025,89:25-44. 12. Perski A, Olsson G, Landou C, et al. Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J. 1992;123:609-16. 13. Palatini P, Reboldi G, Beilin LJ, et al. Predictive value of night-time heart rate for cardiovascular events in hypertension. The ABP-International study. Int J Cardiol. 2013;168:1490-1495. 14. Kikuya M, Ohkubo T, Asayama K, et al. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama study. Hypertension. 2005;45:240-245. 15. Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. J Am Med Assoc. 1999;282:539-546. 16. Fagard RH, Celis H, Thijs L, et al. Daytime and Nighttime Blood Pressure as Predictors of Death and Cause-Specific Cardiovascular Events in Hypertension. Hypertension. 2008;51:55-61. 17. Palatini P, Reboldi G, Beilin LJ, et al. Masked tachycardia. A predictor of adverse outcome in hypertension. J Hypertens. 2017;35:487-492. 18. Eguchi K, Hoshide S, Ishikawa J, et al. Nocturnal nondipping of heart rate predicts cardiovascular events in hypertensive patients. Journal of Hypertension. 2009;27:2265-2270. 19. Ben-Dov IZ, Kark JD, Ben-Ishay D, et al. Blunted heart rate dip during sleep and all-cause mortality. Arch Intern Med. 2007;167:2116-2121. 20. Byun S, Kim AY, Jang EH, et al. Detection of major depressive disorder from linear and nonlinear heart rate variability features during mental task protocol. Comput Biol Med. 2019;112:103381. 21. Mancia G, Kreutz R, Brunström M., et al. 2023 ESH guidelines for the management of arterial hypertension. J. Hypertens. 2023;41:1874-2071. 22. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ASH guideliens for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. 23. Johansen CD, Olsen RH, Pedersen LR, et al. Resting, night- -time, and 24 h heart rate as markers of cardiovascular risk in middle-aged and elderly men and women with no apparent heart disease. Eur Heart J. 2013;34:1732-1739. 24. Palatini P, Palomba D, Bertolo O, et al. The white-coat effect is unrelated to the difference between clinic and daytime blood pressure and is associated with greater reactivity to public speaking. J Hypertens. 2003;21:545-553. 25. Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I epidemiologic follow- -up study. Am Heart J. 1991;121:172-177. 26. Gianaros PJ, Sheu LK. A brain phenotype for stressor-evoked blood pressure reactivity. J Am Heart Assoc. 2017;6:e006053. 27. Fox KM, Ferrari R. Heart rate: a forgotten link in coronary artery disease? Nat Rev Cardiol. 2011;8:369-379. 28. Custodis F, Schirmer SH, Baumhäkel M, et al. Vascular patohysiology in response in inreased heart rate. J Am Coll Cardiol. 2010;56:1973-83. 29. Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens. 1997;15:3-17. 30. Poirier L., Tobe S. W. Contemporary use of β-blockers: clinical relevance of subclassification. Can J Cardiol. 2014;30(5) Suppl.: S9–S15. 31. De la Sierra A, Gorostidi M, Banegas JR, et al. Ambulatory Blood Pressures in Hypertensive Patients Treated With One Antihypertensive Agent: Differences Among Drug Classes and Among Drugs Belonging to the Same Class. J Clin Hypertens.2015;17(11):857-865. 32. Řiháček I, Souček M, Fráň P. Betablokátory v léčbě kardiovaskulárních onemocnění. Medicína pro praxi. 2005;2:58-61. 33. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials Am J Med. 2009 Mar;122(3):290-300. 34. Hradec J. Je nám jasné postavení ivabradinu? Interní Med. 2013;15(8-9):273-276. 35. Blanck P, Stoffel M, Bents H, et al. Heart Rate Variability in Individual Psychotherapy Associations With Alliance and Outcome. J Nerv Ment Dis. 2019;207:451-458. 36. Tylš F. Ketaminem asistovaná psychoterapie v klinické praxi. Psychiatrie. 2025;29:15-22. 37. Frishman WH. Beta-adrenergic blockers: a 50-year historical perspective. Am J Ther. 2008;15(6):565-576. Odborné informace pro vaši praxi – nyní i na Instagramu! Zajímavosti z odborných akcí Odemčené články Klinické kvízy napříč obory Soutěže o předplatné a registrace na kongresy Propojení s komunitou mladých i zkušených lékařů Sledujte nás na @solen_cz a nechte si předepsat medicínu, která vás baví: přehledně, pravidelně a s respektem k vaší odbornosti.
RkJQdWJsaXNoZXIy NDA4Mjc=